EnBiotix
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
EnBiotix was a Boston-based late-clinical-stage biotech co-founded by CEO Jeffrey Wager, built on synthetic-biology antibiotic technology from MIT professor James Collins. It developed engineered antibiotics and potentiators against drug-resistant infections, with an initial focus on chronic respiratory diseases—programs included ColiFin for cystic fibrosis lung infections and inhaled murepavidin. In 2021 it merged with Swiss-listed Polyphor, and the combined company was renamed Spexis AG.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
EnBiotix is formed in Boston to develop engineered antibiotics from James Collins's synthetic-biology platform at MIT.
- Funding round
The company closes an $11 million pre-merger financing led by Vectura Group to fund its ColiFin Phase 3 preparations and merger expenses.
- Restructuring completed
The Polyphor–EnBiotix merger closes and the combined company is renamed Spexis AG, listing on the SIX Swiss Exchange.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.